Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They currently have a $63.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 147.25% from the stock’s previous close. […]

Aquestive Therapeutics (NASDAQ:AQST – Free Report) had its price target hoisted by HC Wainwright from $9.00 to $10.00 in a report published on Monday, Benzinga reports. The firm currently has a buy rating on the stock. Separately, JMP Securities reaffirmed a market outperform rating and issued a $9.00 price objective on shares of Aquestive Therapeutics […]

HC Wainwright restated their buy rating on shares of Zevra Therapeutics (NASDAQ:ZVRA – Free Report) in a research report sent to investors on Monday, Benzinga reports. HC Wainwright currently has a $20.00 target price on the stock. HC Wainwright also issued estimates for Zevra Therapeutics’ Q3 2024 earnings at ($0.50) EPS, Q4 2024 earnings at […]

Ovid Therapeutics (NASDAQ:OVID – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They currently have a $3.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 167.86% from the company’s previous close. […]